Cara, Vifor get EU okay for drug to treat itching in dialysis patients
Vifor Pharma and Cara Therapeutics’ Kapruvia has become the first drug to be approved in the EU to treat one of the most common and […]
Vifor Pharma and Cara Therapeutics’ Kapruvia has become the first drug to be approved in the EU to treat one of the most common and […]
CSL Limited makes many of its therapies from donated plasma, which posed a challenge as pandemic lockdowns led to a steep drop in plasma collections. […]
Australian biotech group CSL has agreed a deal to acquire Swiss drugmaker Vifor Pharma in an all-cash deal that expands its speciality medicines business. If […]
Nephrology products company Vifor Pharma is shelling out about $252 million combined up front to acquire Sanifit Therapeutics and Inositec, developers of drugs for a […]
On the heels of a late-stage clinical trial failure, Vifor Pharma has moved to bolster its pipeline by acquiring Spain’s Sanifit and fell Swiss biotech […]
Vifor Pharma and partner Angion Biomedica have suffered another setback with their drug to prevent organ damage, this time in high-risk kidney transplant patients. A […]
One of the most common and challenging side effects for people undergoing dialysis for chronic kidney disease – chronic itching – now has an FDA-approved […]
The Scottish Medicines Consortium (SMC) has ruled that there’s not enough evidence to support NHS funding of Vifor Pharma’s Veltassa for excess potassium in the […]
Copyright © 2024 | WordPress Theme by MH Themes